Autumn 2026
Special: Autoimmune & inflammatory diseases
Treatment options for autoimmune and inflammatory diseases are evolving from blanket immunosuppression towards more targeted approaches.
Autoimmune and inflammatory diseases remain a major focus for European biotech. Researchers are looking beyond broad immune suppression toward treatments that target the cells and pathways driving disease.
In this special edition of European Biotechnology, we explore how advances in cancer research are finding new uses in immunology, including cell therapies for autoimmune disease. We speak with Immunic CEO Erik Lundgren about the company’s multiple sclerosis program and with Karen Massey, the new CEO of argenx, about what comes next for one of Europe’s most successful autoimmune drug developers.
Together, the stories span early research, late-stage development and the challenge of building a global biotech around treatments for immune disease.
This special is part of the Autumn issue of our magazine.
